Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05948592 · ClinicalTrials.gov registry record · Phase 2
Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection
A Phase 2 study of Diabetic Foot Infection, sponsored by Technophage.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 10
- Study locations
NCT05948592: Completed Phase 2 study of Diabetic Foot Infection, sponsored by Technophage.
NCT05948592 is a Phase 2 study of Diabetic Foot Infection that has completed, run by Technophage. The registered enrollment target is 76 participants, below the 613-participant average among 5 other Diabetic Foot Infection trials with a reported enrollment target (88% lower). The trial reports 10 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05948592, a Phase 2 study of Diabetic Foot Infection, has completed, sponsored by Technophage.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 10
- Study locations
Study Summary
TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii. TP-102 is being developed for topical treatment of patients with wound infections including chronic ulcers; applied every other day (three times weekly (TIW)).
Primary Outcome
See above
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL TP-102
Study Locations (10)
Other
- MV Hospital for Diabetes Pvt. Ltd - Chennai
- GSVM Medical College - Kanpur
- Crescent Hospital & Heart Centre - Nagpur
- Shree Siddhi Vinayak Hospital - Nashik
- Jupiter Hospital & Research Center - Vadodara
- Parikh Multispeciality Healthcare Pvt. Ltd - Vadodara
- Aman Hospital & Research Centre - Vadodara
- Yalamanchi Hospitals & Research Centers Pvt. Ltd - Vijayawada
California
- Clemente Clinical Research - Los Angeles
Texas
- Tranquil Clinical Research - Webster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2025-12-19 |
| Phase | Phase 2 |
What the finished NCT05948592 record still lists
NCT05948592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 613-participant average among 5 other Diabetic Foot Infection trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Diabetic Foot Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05948592 lists 10 locations in 3 states (Other, California, Texas).
Frequently Asked Questions
What is clinical trial NCT05948592 about?
NCT05948592 is a clinical study titled "Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection". TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii. TP-102 is being developed for topical treatment of patients with wound infections including chronic ulcers; applied every other day ...
What is the current status of trial NCT05948592?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2023-11-08. Estimated completion is 2025-12-19.
What conditions does trial NCT05948592 study?
This clinical trial studies the following conditions: Diabetic Foot Infection.
What interventions are being tested in trial NCT05948592?
The interventions under investigation include: Placebo (OTHER), TP-102 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05948592?
This trial is sponsored by Technophage, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05948592 being conducted?
This trial has 10 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
RECRUITING · Phase 3
-
Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis
RECRUITING
-
Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence
RECRUITING
-
Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)
ACTIVE NOT RECRUITING · NA
-
Implementation of Telemedicine for Patient With Lower Extremity Wounds
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI